Dr. Chengcang Charles Wu, founder and CEO of Intact Genomics, spoke at two workshops in PAG XXIX about our newly developed DirectPlate™ technology, which can transform more than 100kb DNA simply, efficiently and without electroporation.
“Analysis of Complex Genomes”
1:30 PM – 3:40 PM, Jan 8, 2022
“Functional Genomics ”
4:00 PM – 6:10 PM, Jan 9, 2022
Intact Genomics is pleased to announce that as of October 15th, 2021, our products will now be available for purchase in Taiwan, via our new distributer Protech Technology Enterprise Co., Ltd. For over 20 years, Protech has been a leader in the developing, manufacturing and marketing of premium quality life sciences solution in Taiwan and became a worldwide supplier.
i-DNA Biotechnology Pte Ltd becomes our new distributor in Singapore and Vietnam; and i-DNA Biotechnology (M) Sdn Bhd (663189-D) is our new distributor in Malaysia. i-DNA, a specialist in research solution, with the headquarter in Singapore and strong business network in the South-East Asia. Its primary focus is to develop, manufacture, market and distribute innovative products and services for applications in the area of life science, biotechnology and laboratory testing.
Our complete product portfolio is now available through Protech Technology Enterprise Co., Ltd and i-DNA Biotechnology. “Intact Genomics strives to provide high-quality products and services to our customers. We look forward to extend our business in Asian and grow our partnership with our distributors, ” says Andy Robertson, Director of Sales at Intact Genomics.
Intact Genomics is pleased to announce that as of August 25th, 2021, our products will now be available for purchase in Germany, Austria and Switzerland through our new distributor, Hölzel Diagnostika in Germany.
Hölzel Diagnostika is a life science reagent supplier founded by biologist Veit Hölzel in the heart of Cologne in 1993. They aim to deliver top notch products that cater to the needs of the Life Science community.
Our complete product portfolio is now available through Hölzel Diagnostika. If you have any questions about ordering through one of our distributors please send your inquires to [email protected].
On Feb 10, 2021, Intact Genomics signed a license agreement with Codex DNA (Formerly known as Synthetic Genomics-DNA) to obtain a non-exclusive license to U.S. Patent Number 7723077 “In Vitro Recombination Method” and other patents. The license allows Intact Genomics to apply the Gibson Assembly method to develop, manufacture and sell its ig-Fusion™ cloning kit and ig-Fusion™ Cloning Enzyme Premix. Intact Genomics propriety ig-Fusion™ cloning technology is a simple, rapid and highly efficient cloning tool.
On February 4th 2021, Intact Genomics announced it had developed Chemically Competent Agrobacterium Cells. These cells will allow researchers to study agrobacterium plant transformations, without the need for an electroporator. These new products will add variety to their robust plant-focused product offerings that already also include Agrobacterium Electrocompetent Cells, Plant Direct PCR Kits and more.
On July 2nd, 2020, Intact Genomics announced it had recently developed a variety of products to assist researchers in their fight against COVID-19. Recently announced products include: FastAmp® Viral/Cell Solution, One Step RT-qPCR Kit for SARS-CoV-2 (COVID-19) detection, and T4 Enzymes (UvsX, UvsY, gp32, and Bsu).
Visit us at Booth 227, and talk with our sales director, Mr. Andy Robertson, and/or CEO, Dr. Chengcang Wu to learn more about our new products, services and technologies. We provide superior molecular biology research tools including agrobacterium competent cells, recombinase polymerase amplification (RPA) optimization enzymes, plant direct PCR kits and custom genomic services to meet your research needs and serve worldwide plant and animal genome R&D community.
Intact Genomics presented at the NIH IntraMalls Fall Showcase and hosted a booth to introduce our new products and technologies including recombinase polymerase amplification (RPA) optimization enzymes on November 7, 2019.
On September 25th, 2019, Intact Genomics announced that the United States Patent and Trademark Office (USPTO) has issued a new patent of “Fungal Artificial Chromosomes, Compositions, Methods and Uses Therefor” (U.S. Patent No. 10,337,019) to Intact Genomics. The patent covers Fungal artificial chromosome (FAC) vectors which can be replicated in a bacterial or a fungal host and can comprise an insert of heterologous DNA up to 300-500 kilobases into a fungal genome. The insert sequence can be modified by homologous recombination. Fungal artificial chromosome (FAC) vectors also can be a plasmid comprising bacterial and fungal origins of replication, as well as bacterial and fungal selection marker genes. Additionally, the patent discloses the methods of generating plasmid libraries including vectors comprising intact SM gene clusters. For more information, click this press release from STLtoday.
Intact Genomics attended “Genomics of Energy & Environment Meeting” hosted by Joint Genome Institute (JGI).
Dr. Chengcang Wu, a Distinguished Scientist from Intact Genomics attended “Genomics of Energy & Environment Meeting” hosted by Joint Genome Institute (JGI) in San Francisco, California from April 2 to April 5, 2019.
Intact Genomics had a poster presentation titled “Unearth Novel Anti-MRSA Antibiotics from Extremophilic Fungi from a Toxic Pit” at the meeting.
